Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study.

Autor: Cabasag CJ; International Agency for Research on Cancer, Lyon, France., Arnold M; International Agency for Research on Cancer, Lyon, France., Rutherford M; International Agency for Research on Cancer, Lyon, France.; Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK., Ferlay J; International Agency for Research on Cancer, Lyon, France., Bardot A; International Agency for Research on Cancer, Lyon, France., Morgan E; International Agency for Research on Cancer, Lyon, France.; Northern Ireland Cancer Registry, Center for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK., Butler J; Royal Marsden Hospital, London, England, UK., O'Connell DL; The Daffodil Center, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia., Nelson G; Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada., Høgdall C; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Schnack T; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Odense University Hospital, Odense, Denmark., Gavin A; Northern Ireland Cancer Registry, Center for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK., Elwood M; Department of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Auckland, New Zealand., Hanna L; Velindre Cancer Center, Cardiff, Wales, UK., Gourley C; Institute of Genetics and Cancer, Cancer Research UK Edinburgh Center, The University of Edinburgh, Edinburgh, Scotland, UK., De P; Ontario Health, Toronto, Canada., Saint-Jacques N; Nova Scotia Health Cancer Care Program, Halifax, Nova Scotia, Canada., Mørch LS; The Danish Cancer Society Research Center, Cancer Surveillance and Pharmacoepidemiology, Copenhagen, Denmark., Woods RR; Cancer Control Research, BC Cancer, Vancouver, British Columbia, Canada., Altman AD; Department of Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Manitoba, Canada.; CancerCare Manitoba Research Institute, Manitoba, Canada., Sykes P; University of Otago, Christchurch, New Zealand., Cohen PA; Department of Gynaecological Oncology, St John of God Subiaco Hospital, Perth, Western Australia, Australia.; Discipline of Obstetrics and Gynaecology, Medical School, University of Western Australia, Perth, Western Australia, Australia., McNally O; Royal Women's Hospital, Melbourne, Australia.; University of Melbourne, Melbourne, Australia., Møller B; Cancer Registry of Norway, Oslo, Norway., Walsh P; National Cancer Registry Ireland, Cork, Ireland., Morrison DS; Scottish Cancer Registry, Scotland, UK., Bray F; International Agency for Research on Cancer, Lyon, France., Soerjomataram I; International Agency for Research on Cancer, Lyon, France.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2023 May 01; Vol. 152 (9), pp. 1763-1777. Date of Electronic Publication: 2023 Jan 23.
DOI: 10.1002/ijc.34403
Abstrakt: The aim of the study is to provide a comprehensive assessment of incidence and survival trends of epithelial ovarian cancer (EOC) by histological subtype across seven high income countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom). Data on invasive EOC diagnosed in women aged 15 to 99 years during 1995 to 2014 were obtained from 20 cancer registries. Age standardized incidence rates and average annual percentage change were calculated by subtype for all ages and age groups (15-64 and 65-99 years). Net survival (NS) was estimated by subtype, age group and 5-year period using Pohar-Perme estimator. Our findings showed marked increase in serous carcinoma incidence was observed between 1995 and 2014 among women aged 65 to 99 years with average annual increase ranging between 2.2% and 5.8%. We documented a marked decrease in the incidence of adenocarcinoma "not otherwise specified" with estimates ranging between 4.4% and 7.4% in women aged 15 to 64 years and between 2.0% and 3.7% among the older age group. Improved survival, combining all EOC subtypes, was observed for all ages combined over the 20-year study period in all countries with 5-year NS absolute percent change ranging between 5.0 in Canada and 12.6 in Denmark. Several factors such as changes in guidelines and advancement in diagnostic tools may potentially influence the observed shift in histological subtypes and temporal trends. Progress in clinical management and treatment over the past decades potentially plays a role in the observed improvements in EOC survival.
(© 2022 International Agency for Research on Cancer. International Agency for Research on Cancer retains copyright and all other rights in the manuscript of this article as submitted for publication.)
Databáze: MEDLINE
Externí odkaz: